Compounds > ochromycinone
Page last updated: 2024-11-12

ochromycinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ochromycinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11808929
CHEMBL ID256705
SCHEMBL ID19799341
MeSH IDM0498937

Synonyms (25)

Synonym
ochromycinone
NCGC00180137-01
ACON1_001791
MEGXM0_000296
j655.169f ,
CHEMBL256705
BRD-K92524032-001-01-3
28882-53-3
(3s)-8-hydroxy-3-methyl-3,4-dihydro-2h-benzo[a]anthracene-1,7,12-trione
benz(a)anthracene-1,7,12(2h)-trione, 3,4-dihydro-8-hydroxy-3-methyl-, (s)-
CKZ6P7I25M ,
(3s)-3.beta.-methyl-8-hydroxy-1,2,3,4,7,12-hexahydrobenzo(a)anthracene-1,7,12-trione
(+)-ochromycinone
unii-ckz6p7i25m
DTXSID40473279
AKOS030254378
J-017311
SCHEMBL19799341
C90290
benz[a]anthracene-1,7,12(2h)-trione, 3,4-dihydro-8-hydroxy-3-methyl-, (3s)-
Q27275510
deoxytetrangomycin
(s)-ochromycinone
CS-0082175
HY-121482
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (10)

Assay IDTitleYearJournalArticle
AID315971Antiproliferative activity against human LNCaP cells after 72 hrs by MTS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Design, synthesis, and studies of small molecule STAT3 inhibitors.
AID315968Inhibition of STAT3 binding to DNA2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Design, synthesis, and studies of small molecule STAT3 inhibitors.
AID315970Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Design, synthesis, and studies of small molecule STAT3 inhibitors.
AID1252744Inhibition of STAT1 (unknown origin) expressed in in IFN-gamma induced human HeLa cells at 50 uM incubated for 1 hr by luciferase reporter gene assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.
AID315969Antiproliferative activity against human DU145 cells after 72 hrs by MTS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Design, synthesis, and studies of small molecule STAT3 inhibitors.
AID318801Antibacterial activity against Bacillus subtilis at 20 to 120 ug/disk2008Journal of natural products, Jan, Volume: 71, Issue:1
Angucyclinones from an Indonesian Streptomyces sp.
AID318803Antibacterial activity against Pseudomonas aeruginosa at 20 to 120 ug/disk2008Journal of natural products, Jan, Volume: 71, Issue:1
Angucyclinones from an Indonesian Streptomyces sp.
AID1252743Inhibition of STAT3 (unknown origin) expressed in Oncostatin M induced human HeLa cells at 50 uM incubated for 1 hr by luciferase reporter gene assay2015European journal of medicinal chemistry, Oct-20, Volume: 103Novel aminotetrazole derivatives as selective STAT3 non-peptide inhibitors.
AID315972Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay2008Bioorganic & medicinal chemistry letters, Jan-01, Volume: 18, Issue:1
Design, synthesis, and studies of small molecule STAT3 inhibitors.
AID702275Inhibition of STAT3 in human MDA-MB-435 cells at 20 uM after 48 hrs by luciferase reporter gene assay relative to untreated control2012Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15
Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (50.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.49 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (87.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
benzene
[no description available]		2.0210aromatic annulene;
benzenes;
volatile organic compound		carcinogenic agent;
environmental contaminant;
non-polar solvent
naphthalene
[no description available]		2.0210naphthalenes;
ortho-fused bicyclic arene		apoptosis inhibitor;
carcinogenic agent;
environmental contaminant;
mouse metabolite;
plant metabolite;
volatile oil component
gold
Gold: A yellow metallic element with the atomic symbol Au, atomic number 79, and atomic weight 197. It is used in jewelry, goldplating of other metals, as currency, and in dental restoration. Many of its clinical applications, such as ANTIRHEUMATIC AGENTS, are in the form of its salts.		7.0210copper group element atom;
elemental gold
tetrangulol
tetrangulol: structure in first source. tetrangulol : A member of the class of tetraphenes that is tetraphene-7,12-dione substituted by hydroxy groups at positions 1 and 8 and a methyl group at position 3.		2.0810p-quinones;
phenols;
tetraphenes		bacterial metabolite
cryptotanshinone
cryptotanshinone: from Salvia miltiorrhiza		3.1710abietane diterpenoidanticoronaviral agent
tetrangomycin
tetrangomycin: RN given for (+)-isomer; structure in first source. tetrangomycin : An angucycline antibiotic that is 3,4-dihydrotetraphene-1,7,12(2H)-trione substituted by hydroxy groups at positions 3 and 8 and a methyl group at position 3 (the 3R stereoisomer) ring system. It is an antibiotic isolated from Streptomyces sp.		7.0310
3,4-dihydro-3-hydroxy-8-methoxy-3-methyl-2h-benz(a)anthracene-1,7,12-trione
MM 47755: from streptomycete isolated from soil; structure given in first source		2.0310
nsc 74859
NSC 74859: inhibits Stat3 binding activity; structure in first source. S3I-201 : An amidobenzoic acid obtained by formal condensation of the carboxy group of [(4-methylbenzene-1-sulfonyl)oxy]acetic acid with the amino group of 4-amino-2-hydroxybenzoic acid.		3.1710amidobenzoic acid;
monohydroxybenzoic acid;
tosylate ester		STAT3 inhibitor
stattic
[no description available]		3.17101-benzothiophenes;
C-nitro compound;
sulfone		antineoplastic agent;
radiosensitizing agent;
STAT3 inhibitor
nifuroxazide
nifuroxazide: structure		3.1710benzoic acids
5,15-diphenylporphine
5,15-diphenylporphine: structure in first source		3.1710
angucyclinone
angucyclinone: structure in first source		2.9640
ConditionIndicatedRelationship StrengthStudiesTrials
Breast Cancer
[description not available]		02.0410
Cancer of Prostate
[description not available]		02.0410
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0410
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.0410
Benign Neoplasms
[description not available]		02.9910
Palmoplantaris Pustulosis
[description not available]		02.9910
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.9910
Psoriasis
A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.		14.9910